Strategy for generation of new TACE inhibitors: Pharmacophore and counter pharmacophore modeling to remove non-selective hits

Medicinal Chemistry Research

Volumn 20, Issue 6, 2011, Pages 760-768

  Bahia, Malkeet Singh ^a   Silakari, Om ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Counter pharmacophore; Pharmacophore modeling; Rheumatoid arthritis; TACE inhibitors

Indexed keywords

INTERSTITIAL COLLAGENASE; LIGAND; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ARTICLE; DATA BASE; DRUG SCREENING; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOPHORE;

EID: 80052022375     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9385-3     Document Type: Article

References (42)

1. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN (1985) Human tumor necrosis factor production, purification and characterization. J Biol Chem 260:2345-2354 (Pubitemid 15104839)
2. Amin AR (1999) Regulation of tumor necrosis factor-α and tumor necrosis factor-a converting enzyme. Osteoarthr Cartil 7:392-394 (Pubitemid 29331558)
3. Ananthula RS, Mutteneni RK, Pramod AB, Madala KK, Mahmood SK (2008) Strategies for generating less toxic P-selectin inhibitors: pharmcophore modeling, virtual screening and counter pharmacophore screening to remove toxic hits. J Mol Graph Model 27:546-557
4. Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717-1725 (Pubitemid 26193625)
5. Bemelhans MHA, Tits LJV, Burrman WA (1996) Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 16: 1-11
6. Black RA (2002) Tumor necrosis factor alpha converting enzyme. Int J Biochem Cell Biol 34:1-5 (Pubitemid 33152908)
7. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloprotease disintegrin that releases tumor necrosis factor alpha from cells. Nature 385:729-733 (Pubitemid 27098094)
8. Brennan FM, Maini RN, Walport M (1992) TNF-α: a pivotal role in rheumatoid arthritis? Br J Rheumatol 31:293-298
9. CATALYST software, version 4.10; Accelrys, Burlington, MA
10. CDOCKER docking programme (CHARMm-based docker) of Discovery Studio 1.7, Accelrys, Burlington, MA
11. Cerius2 software, version 4.10; Accelrys, Burlington, MA
12. Greene J, Kahn S, Savoj H, Spargue P, Teig S (1994) Chemical function queries for 3D database search. J Chem Inf Comput Sci 34:1297-1308
13. Jin G, Huang X, Black R, Wolfson M, Raunch C, McGregor H, Ellestad GA, Cowling R (2002) A continuous fluorimetric assay for tumor necrosis factor alpha converting enzyme. Anal Biochem 302:269
14. Kim J, Remick DG (2007) Tumor necrosis factor inhibitors for treatment of asthma. Curr Allergy Asthma Rep 7:151-156 (Pubitemid 46736337)
15. Letavic MA, Axt MZ, Barberia JT, Carty TJ, Danley DE, Geoghegan KF, Halim NS, Hoth LR, Kamath AV, Laird ER, Lopresti- Morrow LL, McClure KF, Mitchell PG, Natarajan V, Noe MC, Pandit J, Reeves L, Schulte GK, Snow SL, Sweeney FJ, Tan DH, Yu CH (2002) Synthesis and biological activity of selective pipecolic acid based TNF-α converting enzyme (TACE) inhibitors. Bioorg Med Chem Lett 12:1387-1390 (Pubitemid 34454819)
16. Levin JI (2004) The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. Curr Top Med Chem 4: 1289-1310 (Pubitemid 39172338)
17. Levin JI, Chen J, Du M, Hogan M, Kincaid S, Nelson FC, Venkatesan AM, Wehr T, Zask A, DiJoseph J, Killar LM, Skala S, March CJ, Skotnicki JS (2001a) The discovery of anthranilic acid based MMP inhibitors. Part 2: SAR of the 5-position and P1' groups. Bioorg Med Chem Lett 11:2189-2192 (Pubitemid 32763029)
18. Levin JI, Chen JM, Du MT, Nelson FC, Wehr T, DiJoseph JF, Killar LM, Skala S, Sung A, Sharr MA, Roth CE, Jin G, Cowling R, Di L, Sherman M, Xu ZB, March CJ, Mohler KM, Black RA, Skotcicki JS (2001b) The discovery of anthranillic acid based MMP inhibitors. Part 3: incorporation of basic amines. Bioorg Med Chem Lett 11:2975-2978 (Pubitemid 33000109)
19. Levin JI, Chen JM, Du MT, Nelson FC, Killer LM, Skala S, Sung A, Jin G, Cowling R, Barone D, March CJ, Mohler KM, Black RA, Skotnicki JS (2002) Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group. Bioorg Med Chem Lett 12:1199-1202 (Pubitemid 34270563)
20. Levin JI, Chen JM, Cheung K, Cole D, Crago C, Santos ED, Du X, Khafizova G, MacEwan G, Niu C, Salaski EJ, Zask A, Cummons T, Sung A, Xu J, Zhang Y, Xu W, Ayral-Kaloustain S, Jin G, Cowling R, Barone D, Mohler KM, Black RA, Skotnicki JS (2003) Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates. Bioorg Med Chem Lett 13:2799-2803 (Pubitemid 36851573)
21. Levin JI, Nelson FC, Santos ED, Du MT, MacEwan G, Chen JM, Ayral-Kaliustian S, Xu J, Jin G, Cummons T, Barone D (2004) Benzodiazepine inhibitors of the MMPs and TACE. Part 2. Bioorg Med Chem Lett 14:4147-4151 (Pubitemid 38916925)
22. Levin JI, Chen JM, Laakso LM, Du M, Du X, Venkatesan AM, Sandanayaka V, Zask A, Xu J, Xu W, Zhang Y, Skotnicki JS (2005) Acetylenic TACE inhibitors. Part 2: SAR of sixmembered cyclic sulfonamide hydroxamates. Bioorg Med Chem Lett 15:4345-4349 (Pubitemid 41188016)
23. Levin JI, Chen JM, Laakso LM, Du M, Schmid J, Xu W, Commons T, Xu J, Jin G, Barone D, Skotnicki JS (2006) Acetylenic TACE inhibitors. Part 3: thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett 16:1605-1609 (Pubitemid 43197531)
24. Lucas ML, Rothwell NJ, Gibson RM (2006) The role of inflammation in CNS injury and disease. Br J Pharmacol 147:S232-S240 (Pubitemid 43077281)
25. Lukacova V, Zhang Y, Kroll DM, Raha S, Comez D, Balaz S (2005) A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-a converting enzyme: implications for selectivity. J Med Chem 48:2361-2370 (Pubitemid 40516430)
26. Maeda K, Hitora M, Kimura Y, Inoue K, Kuwata K, Ohmuraya M, Gawa M (2003) The effect of TNF-α converting enzyme inhibitors on cytokine response in acute pancreatitis. Int Congr Ser 1255:173-175
27. Maini RN, Brennan FM, Williams R, Chu CQ, Cope AP, Gibbons D, Elliot M, Feldmann M (1993) TNF-α in rheumatoid arthritis andprospects of anti-TNF therapy. Clin Exp Rheumatol 11: S173-S175 (Pubitemid 23136923)
28. Marcia LM, Judith MW, Millard HL, Robert CA (2001) TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today 6:417-426
29. Maskos K, Fernandez-Catalan C, Huber R, Bourenkov G, Bartunik H, Ellestad G, Reddy P, Wolfson M, Rauch C, Castner B, Davis R, Clark H, Peterson M, Fitzner J, Cerratti D, March C, Paxton R, Black R, Bode W (1998) Crystal structure of the catalytic domain of human tumor necrosis factor-α converting enzyme. Proc Natl Acad Sci USA 95:3408-3412 (Pubitemid 28173141)
30. Moss ML, Jin SLC, Milla ME, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA (1997) Clonning of a disintegrin metalloprotease that posses precursor tumor necrosis factor alpha. Nature 385:733-736
31. Nelson FC, Zask A (1999) The therapeutic potential of small molecule TACE inhibitors. Expert Opin Invest Drugs 8:383-392 (Pubitemid 29164244)
32. Nelson FC, Santos ED, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD (2002) Benzodiazepine inhibitors of MMPs and TACE. Bioorg Med Chem Lett 12:2867-2870
33. Newton RC, Solomon KA, Covington MB, Deccico CP, Haley PJ, Friedman SM, Vaddi K (2001) Biology of TACE inhibition. Ann Rheum Dis 60:417-426
34. Opera TI (2002) Virtual screening in lead discovery: a viewpoint. Molecules 7:51-62
35. Renkiewicz R, Qiu L, Lesch C, Un X, Devalaraja R, Cody T, Kaldjian E, Welgus H, Baragi V (2003) Broad spectrum matrix metalloproteinase inhibitor marimastat induced musculoskeletal side effects in rats. Arthr Rheum 48:1742-1749 (Pubitemid 36682383)
36. Rink L, Kirchner H (1996) Recent progress in tumor necrosis factor-a field. Int Arch Allergy Immunol 111:199-209 (Pubitemid 26345377)
37. Sekut L, Connolly KM (1996) Pathophysiology and regulation of TNF-α in inflammation. Drug News Perspect 9:261-269
38. Smellie A, Teig SL, Towbin P (1995) Poling: promoting conformational coverage. J Comput Chem 16:171-187
39. van Deventer SJH (2002) A place of TACE. GUT 51:5-6
40. Yamamoto M, Tsuijishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y (1998) Inhibition of membrane type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J Med Chem 41:1209-1217 (Pubitemid 28208176)
41. Zask A, Gu Y, Albright JD, Du X, Hogan M, Levin JI, Chen JM, Killar LM, Sung A, DiJoseph JF, Sharr MA, Roth CE, Skala S, Jin G, Cowling R, Mohler KM, Barone D, Black R, March C, Skotnicki JS (2003) Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors. Bioorg Med Chem Lett 13:1487-1490 (Pubitemid 36369195)
42. Zask A, Kaplan J, Du X, MacEwan G, Sandanayaka V, Eudy N, Levin J, Jin G, Xu J, Cummons T, Barone D, Aayral-Kaloustian S, Skotnicki J (2005) Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors. Bioorg Med Chem Lett 15:1641-1645 (Pubitemid 40312545)